PMID- 23647006
OWN - NLM
STAT- MEDLINE
DCOM- 20140402
LR  - 20130822
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 12
IP  - 5
DP  - 2013 Sep
TI  - Indications and safety of proton pump inhibitor drug use in patients with cancer.
PG  - 659-72
LID - 10.1517/14740338.2013.797961 [doi]
AB  - INTRODUCTION: Although the exact prevalence of proton pump inhibitor (PPI) use in 
      cancer patients is not known, it is generally perceived to be widespread. PPIs 
      are generally well tolerated and carry an excellent safety profile. However, 
      increasing and longer term PPI use has raised concerns about the risk of 
      pneumonia, bone fractures and enteric infections, and a possible interaction with 
      clopidogrel that could increase the risk of cardiovascular events. AREAS COVERED: 
      We conducted a PubMed search of English language articles addressing the safety 
      and adverse events associated with PPI use with particular emphasis in cancer 
      patients. EXPERT OPINION: PPIs, frequently used in cancer patients, are generally 
      well tolerated and carry an excellent safety profile. PPI-induced acid 
      suppression may increase the risk of Clostridium difficile or other enteric 
      infections, nutritional deficiencies and community acquired pneumonia, all 
      particularly important in cancer patients. The indications for PPI use in cancer 
      patients should be carefully reviewed prior to use.
FAU - Triadafilopoulos, George
AU  - Triadafilopoulos G
AD  - Stanford University Medical Center, Division of Gastroenterology, 300 Pasteur 
      Drive, # M-211, Stanford, CA 94305, USA. vagt@stanford.edu
FAU - Roorda, Andrew K
AU  - Roorda AK
FAU - Akiyama, Junichi
AU  - Akiyama J
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20130507
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Humans
MH  - Neoplasms/*drug therapy
MH  - Proton Pump Inhibitors/*adverse effects/*therapeutic use
EDAT- 2013/05/08 06:00
MHDA- 2014/04/03 06:00
CRDT- 2013/05/08 06:00
PHST- 2013/05/08 06:00 [entrez]
PHST- 2013/05/08 06:00 [pubmed]
PHST- 2014/04/03 06:00 [medline]
AID - 10.1517/14740338.2013.797961 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2013 Sep;12(5):659-72. doi: 10.1517/14740338.2013.797961. 
      Epub 2013 May 7.